Verona Pharma

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Verona Pharma excels in COPD trials, secures funding for growth

Verona Pharma's strong performance in Phase 3 trials and solid financial position set a positive trajectory for future growth and NDA submission.
While facing competition and addressing various challenges, the company's strategic vision and upcoming milestones offer opportunities for expansion and partnerships.

Verona Pharma reports strong Q1 earnings, gears up for ensifentrine launch

Verona Pharma's Q1 2023 earnings call highlighted strong financial performance, progress towards NDA submission for ensifentrine, and strategic initiatives for the upcoming launch.
Despite facing challenges in managing expenses and navigating regulatory processes, the company remains optimistic about its market positioning and growth prospects.
With a focus on differentiation, global partnerships, and commercial readiness, Verona Pharma is poised for success in the COPD treatment market in 2024 and beyond.
The company's emphasis on marketing, operational setup, and post-ENHANCE data promotion underscores its commitment to maximizing market impact and revenue potential.

Verona Pharma advances ensifentrine with strong Q2 performance and global expansion prospects

Verona Pharma's Q2 2023 performance showcased progress on ensifentrine and a strong financial position, despite a net loss driven by ongoing expenses.
Strengths include positive trial results, a robust cash position, and global expansion efforts, while challenges lie in financial management and regulatory uncertainties.
Opportunities abound in FDA approval prospects, market expansion through subgroup usage, reimbursement optimization, and product portfolio expansion.
Analysts' inquiries highlighted key concerns and strategic considerations for Verona Pharma's future growth and commercial success in the COPD treatment market.

Verona Pharma advances towards FDA approval with strong financials

Verona Pharma progresses towards FDA approval for ensifentrine, with a set action date.
Financially stable with cash reserves and plans for a robust sales force.
Balancing R&D investments with increased expenses and strategic challenges.
Positioned for growth with pipeline expansion and positive data on treatment impact.

Verona Pharma excels in Q4, eyes FDA approval for ensifentrine

Verona Pharma's Q4 2023 earnings call highlighted strong financials, progress with ensifentrine's FDA submission, and strategic plans for commercial launch and market positioning. While facing challenges in FDA review and commercial strategy, the company remains optimistic about ensifentrine's market prospects and growth opportunities.

Verona Pharma excels in Q1 with ensifentrine progress and financial strength

Verona Pharma's Q1 2024 performance highlighted progress on ensifentrine, strong commercial launch preparations, and a robust financial position.
Strengths lie in ensifentrine's novelty, disease awareness focus, and the company's solid financial foundation.
Challenges include addressing analyst queries, market competition, and ensuring a successful commercial launch.
Opportunities abound in leveraging ensifentrine's utility, financial strength, and the potential for market disruption in COPD treatment.

Verona Pharma reports strong Ohtuvayre sales but faces challenges

Verona Pharma's Q3 2024 earnings call highlighted strong net product sales for Ohtuvayre, but also revealed a net loss after tax. The company's successful launch of Ohtuvayre and progress in new trials and partnerships demonstrate potential for growth. However, Verona Pharma faces challenges in addressing various aspects of its business and potential competition in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Funding to support Phase 3 ENHANCE clinical program in COPD Funding to support Phase 3 ENHANCE clinical program in COPD

Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription

LONDON, July  06, 2020  (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it has issued 55,000 ordinary shares of 5 pence each (the “New Ordinary Shares”) following the vesting of restricted stock units held by a former employee.

Verona Pharma plc: Issue of Equity and Total Voting Rights

LONDON, May  12, 2020  (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it has on May 7, 2020 granted to Dr David Zaccardelli, CEO, and Mr Mark Hahn, CFO of the Company, an aggregate of 921,608 Restricted American Depositary Share Units (“RADSUs”), representing 7,372,864 ordinary shares of 5 pence each (the “Ordinary Shares”), and today issued to them an aggregate of 267,288 ordinary shares of 5 pence each (the “New Ordinary Shares”) following the vesting of previously granted RADSUs.

Director/PDMR Shareholding - Grant of Restricted Stock Units, Issue of Equity, Total Voting Rights & PDMR Dealings

Verona Pharma plc (VRNA) CEO David Zaccardelli on Q1 2020 Results - Earnings Call Transcript

Analysis supports ensifentrine’s efficacy in COPD as monotherapy and on top of standard of care treatment in patients who remain symptomatic

Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic Society 2020 International Conference

LONDON, April  16, 2020  (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that all resolutions proposed at the Annual General Meeting held today were duly approved by shareholders by way of a poll. The  results of the poll  are available on the Investors section of the Company’s website, www.veronapharma.com.

Verona Pharma plc: Results of AGM

LONDON, April  08, 2020  (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, provides an update on its upcoming Annual General Meeting (“AGM”), scheduled to be held at the offices of Shakespeare Martineau at 60 Gracechurch Street, London EC3V 0HR, United Kingdom at 10.30 a.m. on April 16, 2020.

Update on AGM Procedure

Statistically significant and clinically meaningful improvements in lung function

Verona Pharma  Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD

Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD

LONDON, March  16, 2020  (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, is pleased to confirm that a hard copy of the Annual Report and Accounts for the year ended December 31, 2019 ("2019 Annual Report and Accounts"), the Notice of Annual General Meeting and a Form of Proxy have been mailed to Shareholders of record as of March 13, 2020.

2019 Annual Report and Accounts and Notice of AGM

LONDON, March  05, 2020  (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 3, 2020, it granted Restricted Stock Units in the form of an aggregate of 133,648 Restricted American Depositary Share Units (“RADSUs”) to Dr David Zaccardelli and Mr Mark Hahn under and in accordance with the terms of Verona Pharma’s 2017 Incentive Award Plan (the “Incentive Plan”). Details of the Incentive Plan are contained in the Company’s 2019 Annual Report and 20-F SEC filing, both of which are available on the “Investors” section of the Company’s website ( https://www.veronapharma.com/investors/news-sec-filings  ). Each RADSU represents an unfunded, unsecured right to receive, on the applicable vesting date, one American Depositary Share (“ADS”), or, at the option of the Company, an equivalent amount in cash.

Grant of Restricted Stock Units and PDMR Dealings

Verona Pharma plc (VRNA) CEO David Zaccardelli on Q4 2019 Results - Earnings Call Transcript

Vectoring In On Verona Pharma

Paper demonstrates ensifentrine’s potential in improving lung function and quality of life symptoms Paper demonstrates ensifentrine’s potential in improving lung function and quality of life symptoms

Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research

LONDON, Feb.  07, 2020  (GLOBE NEWSWIRE) -- TR-1: S tandard form for notification of major holdings

Holding(s) in Company TR-1: Standard form for notification of major holdings

Dr. David Zaccardelli appointed President and Chief Executive Officer

Verona Pharma Announces Senior Management Changes

LONDON, Jan.  17, 2020  (GLOBE NEWSWIRE) -- TR-1: S tandard form for notification of major holdings

Holding(s) in Company TR-1:  Standard form for notification of major holdings

Verona Pharma   surged 69% in London trade as the biopharma said a Phase 2b study evaluating a drug for chronic obstructive pulmonary disease met its primary endpoint of improved lung function.

Verona Pharma shares shoot higher on Phase 2 trial of respiratory drug

Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant dose-dependent improvements in lung function

Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy

LONDON, Jan.  07, 2020  (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the appointment of David Moskowitz to the newly created position of Vice President, Capital Markets Strategy & Investor Relations. Mr. Moskowitz will oversee the Company’s investor relations activities and will also work with the senior leadership team to further develop Verona Pharma’s public market profile.

Verona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor Relations

LONDON, Nov.  28, 2019  (GLOBE NEWSWIRE) -- TR-1: S tandard form for notification of major holdings

Holding(s) in Company TR-1: Standard form for notification of major holdings.

LONDON, Nov.  27, 2019  (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that, on November 26, 2019, it granted 500,000 options to purchase ordinary shares of £0.05 each (the “Ordinary Shares”) to its CEO, Dr. Jan-Anders Karlsson, under and in accordance with Verona Pharma’s 2017 Incentive Award Plan (which is set out in Verona Pharma’s 2018 annual report and 20-F) (the “Options”).

Verona Pharma plc: Grant of Options to PDMR

LONDON, Nov.  18, 2019  (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Dr. David Ebsworth, Chairman of the Company, has notified the Company that he has purchased a further 25,000 ordinary shares of 5 pence each in the Company (“Ordinary Shares”) at a total purchase price of £11,750, at a price of 47 pence per Ordinary Share. This purchase brings the total purchases made by Dr. Ebsworth during 2019 to approximately £125,000.

Verona Pharma plc: PDMR Dealing – Purchase by Chairman

Verona Pharma plc (VRNA) CEO Jan-Anders Karlsson on Q3 2019 Results - Earnings Call Transcript

Reported positive Phase 2 data with dry powder inhaler formulation

News for Verona Pharma Stock (VRNA)